The Hyderabad-based drug firm informed exchanges that it has received an ... Axis Capital, in a research report, said it expects recovery for most Indian Pharma companies by September quarter of financial year 2018 (Q2FY18).
Read more: Pharma stocks soar after USFDA, other approvals